EDIT - Editas Medicine, Inc.
| Previous Close | 19.83 |
| Open | 19.86 |
| Bid | 20.18 x 800 |
| Ask | 20.25 x 1400 |
| Day's Range | 19.85 - 20.33 |
| 52 Week Range | 17.80 - 32.46 |
| Volume | 52,576 |
| Avg. Volume | 618,444 |
| Market Cap | 1.005B |
| Beta (3Y Monthly) | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- GlobeNewswire
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
Editas Medicine, Inc. (EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia. Under the terms of the agreement, Editas Medicine obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop up to five therapies including four immuno-oncology therapies, and in return MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.
- GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 01, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following.
- Zacks
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
- Zacks
ETFs Poised to Benefit from Gene Editing Revolution
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
- Zacks
Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Need To Know: Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Have Been Buying Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- MarketWatch
CRISPR gene-editing technique set to push new boundaries
CRISPR is a gene-editing technique that enables the targeting and editing of specific sequences in the human DNA. It has been around for a couple of years, and recently, researchers in the U.S. have started using it to alter the genes of adults suffering from progressive disorders and diseases. The scientific community largely shunned the experiment, as CRISPR is known to result in unwanted gene edits, which, in the case of embryos (as well as sperm and eggs), are carried over to their offspring.
- Thomson Reuters StreetEvents
Edited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMT
Q2 2019 Editas Medicine Inc Earnings Call
- GlobeNewswire
Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif., Aug. 12, 2019 -- Dynavax.
Motley FoolEditas Medicine, Inc. (EDIT) Q2 2019 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2019.
- Zacks
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
- Motley Fool
Editas Medicine Remains on Track
With a new CEO in place and a groundbreaking "in vivo" dosing study approaching, the gene-editing leader is rightly excited for the future.
- Zacks
Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Editas Medicine Announces Second Quarter 2019 Results and Update
Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in.
- Motley Fool
Is Intellia Therapeutics a Buy?
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
- GlobeNewswire
Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., July 30, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
- Zacks
Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the Brilliance Phase 1/2 clinical trial of AGN-151587 (EDIT-101) is open for patient enrollment. AGN-151587 is an experimental medicine under development for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited form of blindness caused by mutations in the CEP290 gene. The clinical trial will be the world’s first in vivo study of a CRISPR-based genome editing medicine, where the editing takes place inside the human body.
- Motley Fool
CRISPR Could Change Medicine, But Not in the Way Wall Street Expects
The gene-editing approach might prove more useful outside the clinic.
- Motley Fool
Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
- Motley Fool
Is Editas Medicine a Buy?
High risk? Definitely. But this small biotech also has the potential for high returns over the long run.
